Well, Actually: Your Next Filler Might Come From a Cadaver, and the Koreans Are Already Doing It
A South Korean injectable called Elravie RE2O uses donated human dermis. The product has gained popularity there and its manufacturer, Hugel, is reportedly pursuing US market entry. The material comes from cadaveric skin that has been processed and sterilized.
This illustrates how regulatory arbitrage shapes biomedical innovation. You should watch where therapies debut first, as that signals both cultural acceptance thresholds and regulatory pathway feasibility. The lag between Korean and US availability creates information asymmetries that savvy observers can exploit.
Hugel, a South Korean biopharmaceutical company, manufactures Elravie RE2O. The product is already in use in the South Korean market.
Step 1: Search 'FDA approved dermal fillers' on the FDA website to compare approved materials against experimental ones. Step 2: Read the patient labeling for any filler you are considering to identify its source material, whether synthetic, animal-derived, or human-derived. Step 3: Ask your provider specifically about the origin of any proposed injectable and whether it holds FDA approval for your intended use, documenting the response.